ERYTECH Pharma S.A.

Registration Form • Apr 30, 2016

ERYTECH makes its 2015 Reference Document available

Lyon (France), April 30, 2016 – ERYTECH (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company developing innovative 'tumor starvation' treatments for acute leukemia and other oncology indications with unmet medical needs, today announced that it had filed on April 29, 2016 with the "Autorité des Marchés Financiers (AMF)", its 2015 Reference Document, including the management report and the annual financial report.

The Reference Document is available on the Company's website (http://erytech.com/referencedocuments.html ) and on the AMF website (http://www.amf-france.org). The document is also available free of charge, by sending a postal request to the registered offices of ERYTECH Pharma, Bâtiment Adénine, 60 Avenue Rockefeller, 69008 in Lyon (France).

The following documents are included in the 2015 Reference Document:

• the annual financial report;
• the management report;
• Information about fees paid to statutory auditors;
• the report of the Chairman of the Board of Directors on corporate governance and internal control;
• the auditors' report on the report of the Chairman of the Board of Directors;
• Description of the share buy-back program;
• the Company's policies on environmental, social and corporate responsibility.

CONTACTS

ERYTECH	NewCap
Gil Beyen	Julien Perez / Emmanuel Huynh
Chairman and CEO	Investor relations
Tel: +33 4 78 74 44 38	Nicolas Merigeau
investors@erytech.com	Press relations
	Tel: +33 1 44 71 98 52
	erytech@newcap.fr

Risk factors

ERYTECH draws the public's attention to the business-related risks described in Chapter 4 'Risk Factors' of its 2015 Reference Document.

Forward-looking information

This document may contain forward-looking statements and estimates with respect to the financial position, results of operations, business strategy, plans, objectives and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Documents filed by ERYTECH Pharma with the French Autorité des Marchés Financiers (www.amffrance.org), also available on ERYTECH's website (www.erytech.com) describe such risks and uncertainties. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. Readers are cautioned not to place undue reliance on any of these forwardlooking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH's expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.